LONDON (Alliance News) - Faron Pharmaceuticals Ltd Thursday said it has expanded its development strategy for its cancer immunotherapy drug candidate Clevegen.
After filing patents opening up new application opportunities for Clevegen, Faron plans to extend its range of Clevegen indications through what it calls its tumour immunity enabling technology, or TIET, which can be used alone or combined with other immune checkpoint molecules.
Faron plans to develop Clevegen in-house for immune dependent cancers like hepatocellular carcinoma.
"We have made significant progress with Clevegen this spring, culminating in development of the new TIET technology platform. We will intensify our efforts in commercialising the TIET technology globally while also initiating our own cancer treatment programme," said Chief Executive Officer Markku Jalkanen in a statement.
Shares in Faron were untraded Thursday morning. They last traded at 250.00 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)